These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 20038269)

  • 1. Osteoblastogenesis and tumor growth in myeloma.
    Yaccoby S
    Leuk Lymphoma; 2010 Feb; 51(2):213-20. PubMed ID: 20038269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
    Pennisi A; Li X; Ling W; Khan S; Zangari M; Yaccoby S
    Am J Hematol; 2009 Jan; 84(1):6-14. PubMed ID: 18980173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orthopaedics: Structural support.
    Berglund J
    Nature; 2011 Dec; 480(7377):S56-7. PubMed ID: 22169807
    [No Abstract]   [Full Text] [Related]  

  • 5. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
    Munemasa S; Sakai A; Kuroda Y; Okikawa Y; Katayama Y; Asaoku H; Kubo T; Shimose S; Kimura A
    Int J Oncol; 2008 Jul; 33(1):129-36. PubMed ID: 18575758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the bone marrow microenvironment in multiple myeloma.
    Roodman GD
    J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to bortezomib and activation of osteoblasts in multiple myeloma.
    Zangari M; Yaccoby S; Cavallo F; Esseltine D; Tricot G
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):109-14. PubMed ID: 17026821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
    Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
    Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib.
    Nakamura S; Miki H; Kido S; Nakano A; Hiasa M; Oda A; Amou H; Watanabe K; Harada T; Fujii S; Takeuchi K; Kagawa K; Ozaki S; Matsumoto T; Abe M
    Int J Hematol; 2013 Jul; 98(1):66-73. PubMed ID: 23708974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of bortezomib on bone disease in patients with multiple myeloma.
    Mohty M; Malard F; Mohty B; Savani B; Moreau P; Terpos E
    Cancer; 2014 Mar; 120(5):618-23. PubMed ID: 24249482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma.
    Lee SE; Min CK; Yahng SA; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Park CW
    Eur J Haematol; 2011 Jan; 86(1):83-6. PubMed ID: 20946110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
    Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
    Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
    Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
    J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.
    Pennisi A; Li X; Ling W; Khan S; Gaddy D; Suva LJ; Barlogie B; Shaughnessy JD; Aziz N; Yaccoby S
    Br J Haematol; 2009 Jun; 145(6):775-87. PubMed ID: 19388929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.
    Kaiser MF; Heider U; Mieth M; Zang C; von Metzler I; Sezer O
    Eur J Haematol; 2013 Apr; 90(4):263-72. PubMed ID: 23311753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.
    Pennisi A; Ling W; Li X; Khan S; Wang Y; Barlogie B; Shaughnessy JD; Yaccoby S
    PLoS One; 2010 Dec; 5(12):e15233. PubMed ID: 21188144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the understanding of myeloma bone disease and tumour growth.
    Yaccoby S
    Br J Haematol; 2010 May; 149(3):311-21. PubMed ID: 20230410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.
    Faict S; Muller J; De Veirman K; De Bruyne E; Maes K; Vrancken L; Heusschen R; De Raeve H; Schots R; Vanderkerken K; Caers J; Menu E
    Blood Cancer J; 2018 Nov; 8(11):105. PubMed ID: 30409995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.
    Heider U; Kaiser M; Müller C; Jakob C; Zavrski I; Schulz CO; Fleissner C; Hecht M; Sezer O
    Eur J Haematol; 2006 Sep; 77(3):233-8. PubMed ID: 16923110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple myeloma: interplay between osteoblastogenesis and adipogenesis.
    Kaiafa G; Dokos C; Hatzitolios A; Savopoulos C
    Eur J Haematol; 2011 May; 86(5):447-8. PubMed ID: 21323739
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.